Lisata Therapeutics
LSTA
30 hedge funds and large institutions have $1.11M invested in Lisata Therapeutics in 2016 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 5 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
7% more funds holding
Funds holding: 28 → 30 (+2)
0.32% more ownership
Funds ownership: 0% → 0.32% (+0.32%)
48% less capital invested
Capital invested by funds: $2.15M → $1.11M (-$1.04M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$167K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$79.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$60.4K |
| 4 |
Goldman Sachs
New York
|
+$42.6K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$41.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Hollencrest Capital Management
Newport Beach,
California
|
-$570K |
| 2 |
EGA
Eagle Global Advisors
Houston,
Texas
|
-$127K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$66K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$46K |
| 5 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
-$22K |
LSTA Hedge Fund Activity: Q4 2016 in Review
30 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q4 2016, worth a combined $1.11M — down 48% from $2.15M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new LSTA positions and 5 closed out — a net gain of 2 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $167K. The largest seller was Hollencrest Capital Management, exiting entirely with an estimated $570K sold.
- 30 institutional investors held Lisata Therapeutics (LSTA) as of Q4 2016, up from 28 in Q3 2016.
- Funds reported $1.11M of Lisata Therapeutics stock for Q4 2016, down 48% quarter-over-quarter.
- 7 funds opened new Lisata Therapeutics positions in Q4 2016 and 5 closed out, a net change of +2 holders.
- The largest Lisata Therapeutics buyer in Q4 2016 was Renaissance Technologies, an estimated $167K added.
- The largest Lisata Therapeutics seller in Q4 2016 was Hollencrest Capital Management, an estimated $570K sold.
Based on aggregated 13F filings for Q4 2016.